UPDATE: RBC Capital Starts Editas Medicine (EDIT) at Sector Perform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to UPDATE: RBC Capital Starts Editas Medicine (EDIT) at Sector Perform

Editas Medicine (EDIT) Misses Q1 EPS by 13c, Revenues Beat

May 5, 2021 7:24 AM EDT

Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.86), $0.13 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $6.5 million versus the consensus estimate of $5.77 million.

Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicines, including excellent forward momentum this quarter for our two clinical-stage... More